The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Human Papillomavirus Vaccine (Types 16, 18) Market Research Report 2024
Synopsis
Human papillomavirus vaccine (16, 18 types) is a vaccine that can prevent 16, 18 types of human papillomavirus infection. Prophylactic HPV vaccination can effectively reduce 16, 18 types of human papillomavirus infection and related clinical diseases. Inoculation of human papillomavirus vaccines (types 16 and 18) can stimulate the body to produce neutralizing antibodies. When human papillomavirus invades the human body, the neutralizing antibodies can recognize the virus and bind to it, clear the virus through neutralization, and prevent organ failure. Neck cancer, penile cancer, vulvar cancer, oropharyngeal cancer, reproductive Shen and other diseases caused by human papillomavirus infection.
The global Human Papillomavirus Vaccine (Types 16, 18) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Human papillomavirus vaccine (types 16, 18) is a preventive vaccine that can effectively prevent HPV infection, thereby preventing cervical cancer and other HPV-related cancers. The prevention and treatment of cervical cancer and other HPV-related cancers have undergone major advances due to the development of human papillomavirus vaccines (types 16, 18). The development of human papillomavirus vaccines (types 16, 18) has received global attention and many countries have included it in their national immunization programmes. Over the past few years, the human papillomavirus vaccine (types 16, 18) has achieved great success, and the incidence of cervical cancer and other HPV-related cancers has decreased significantly worldwide. As the HPV vaccine becomes more widely available, its prospects are very promising. Global HPV vaccination rates are expected to increase further and the incidence of cervical cancer and other HPV-related cancers to continue to decline in the coming years. In addition, the development of human papillomavirus vaccines (types 16, 18) will bring additional social and economic benefits, including reducing medical expenditures and improving public health.
This report aims to provide a comprehensive presentation of the global market for Human Papillomavirus Vaccine (Types 16, 18), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Papillomavirus Vaccine (Types 16, 18).
Report Scope
The Human Papillomavirus Vaccine (Types 16, 18) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Papillomavirus Vaccine (Types 16, 18) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Papillomavirus Vaccine (Types 16, 18) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GlaxoSmithKline
Merck & Co., Inc.
Serum Institute of India
INNOVAX
ZSSW
HUMANWELL HEALTHCARE
WALVAX
Segment by Type
HPV16
HPV18
Segment by Application
9-26 Years Old
26-45 Years Old
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Human Papillomavirus Vaccine (Types 16, 18) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Human Papillomavirus Vaccine (Types 16, 18) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Human papillomavirus vaccine (16, 18 types) is a vaccine that can prevent 16, 18 types of human papillomavirus infection. Prophylactic HPV vaccination can effectively reduce 16, 18 types of human papillomavirus infection and related clinical diseases. Inoculation of human papillomavirus vaccines (types 16 and 18) can stimulate the body to produce neutralizing antibodies. When human papillomavirus invades the human body, the neutralizing antibodies can recognize the virus and bind to it, clear the virus through neutralization, and prevent organ failure. Neck cancer, penile cancer, vulvar cancer, oropharyngeal cancer, reproductive Shen and other diseases caused by human papillomavirus infection.
The global Human Papillomavirus Vaccine (Types 16, 18) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Human papillomavirus vaccine (types 16, 18) is a preventive vaccine that can effectively prevent HPV infection, thereby preventing cervical cancer and other HPV-related cancers. The prevention and treatment of cervical cancer and other HPV-related cancers have undergone major advances due to the development of human papillomavirus vaccines (types 16, 18). The development of human papillomavirus vaccines (types 16, 18) has received global attention and many countries have included it in their national immunization programmes. Over the past few years, the human papillomavirus vaccine (types 16, 18) has achieved great success, and the incidence of cervical cancer and other HPV-related cancers has decreased significantly worldwide. As the HPV vaccine becomes more widely available, its prospects are very promising. Global HPV vaccination rates are expected to increase further and the incidence of cervical cancer and other HPV-related cancers to continue to decline in the coming years. In addition, the development of human papillomavirus vaccines (types 16, 18) will bring additional social and economic benefits, including reducing medical expenditures and improving public health.
This report aims to provide a comprehensive presentation of the global market for Human Papillomavirus Vaccine (Types 16, 18), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Papillomavirus Vaccine (Types 16, 18).
Report Scope
The Human Papillomavirus Vaccine (Types 16, 18) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Papillomavirus Vaccine (Types 16, 18) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Papillomavirus Vaccine (Types 16, 18) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GlaxoSmithKline
Merck & Co., Inc.
Serum Institute of India
INNOVAX
ZSSW
HUMANWELL HEALTHCARE
WALVAX
Segment by Type
HPV16
HPV18
Segment by Application
9-26 Years Old
26-45 Years Old
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Human Papillomavirus Vaccine (Types 16, 18) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Human Papillomavirus Vaccine (Types 16, 18) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Human Papillomavirus Vaccine (Types 16, 18) Market Overview
1.1 Product Overview and Scope of Human Papillomavirus Vaccine (Types 16, 18)
1.2 Human Papillomavirus Vaccine (Types 16, 18) Segment by Type
1.2.1 Global Human Papillomavirus Vaccine (Types 16, 18) Market Value Comparison by Type (2024-2030)
1.2.2 HPV16
1.2.3 HPV18
1.3 Human Papillomavirus Vaccine (Types 16, 18) Segment by Application
1.3.1 Global Human Papillomavirus Vaccine (Types 16, 18) Market Value by Application: (2024-2030)
1.3.2 9-26 Years Old
1.3.3 26-45 Years Old
1.4 Global Human Papillomavirus Vaccine (Types 16, 18) Market Size Estimates and Forecasts
1.4.1 Global Human Papillomavirus Vaccine (Types 16, 18) Revenue 2019-2030
1.4.2 Global Human Papillomavirus Vaccine (Types 16, 18) Sales 2019-2030
1.4.3 Global Human Papillomavirus Vaccine (Types 16, 18) Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Human Papillomavirus Vaccine (Types 16, 18) Market Competition by Manufacturers
2.1 Global Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Manufacturers (2019-2024)
2.2 Global Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Human Papillomavirus Vaccine (Types 16, 18) Average Price by Manufacturers (2019-2024)
2.4 Global Human Papillomavirus Vaccine (Types 16, 18) Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Human Papillomavirus Vaccine (Types 16, 18), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Human Papillomavirus Vaccine (Types 16, 18), Product Type & Application
2.7 Human Papillomavirus Vaccine (Types 16, 18) Market Competitive Situation and Trends
2.7.1 Human Papillomavirus Vaccine (Types 16, 18) Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Human Papillomavirus Vaccine (Types 16, 18) Players Market Share by Revenue
2.7.3 Global Human Papillomavirus Vaccine (Types 16, 18) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Human Papillomavirus Vaccine (Types 16, 18) Retrospective Market Scenario by Region
3.1 Global Human Papillomavirus Vaccine (Types 16, 18) Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Human Papillomavirus Vaccine (Types 16, 18) Global Human Papillomavirus Vaccine (Types 16, 18) Sales by Region: 2019-2030
3.2.1 Global Human Papillomavirus Vaccine (Types 16, 18) Sales by Region: 2019-2024
3.2.2 Global Human Papillomavirus Vaccine (Types 16, 18) Sales by Region: 2025-2030
3.3 Global Human Papillomavirus Vaccine (Types 16, 18) Global Human Papillomavirus Vaccine (Types 16, 18) Revenue by Region: 2019-2030
3.3.1 Global Human Papillomavirus Vaccine (Types 16, 18) Revenue by Region: 2019-2024
3.3.2 Global Human Papillomavirus Vaccine (Types 16, 18) Revenue by Region: 2025-2030
3.4 North America Human Papillomavirus Vaccine (Types 16, 18) Market Facts & Figures by Country
3.4.1 North America Human Papillomavirus Vaccine (Types 16, 18) Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Human Papillomavirus Vaccine (Types 16, 18) Sales by Country (2019-2030)
3.4.3 North America Human Papillomavirus Vaccine (Types 16, 18) Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Human Papillomavirus Vaccine (Types 16, 18) Market Facts & Figures by Country
3.5.1 Europe Human Papillomavirus Vaccine (Types 16, 18) Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Human Papillomavirus Vaccine (Types 16, 18) Sales by Country (2019-2030)
3.5.3 Europe Human Papillomavirus Vaccine (Types 16, 18) Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Human Papillomavirus Vaccine (Types 16, 18) Market Facts & Figures by Country
3.6.1 Asia Pacific Human Papillomavirus Vaccine (Types 16, 18) Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Human Papillomavirus Vaccine (Types 16, 18) Sales by Country (2019-2030)
3.6.3 Asia Pacific Human Papillomavirus Vaccine (Types 16, 18) Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Human Papillomavirus Vaccine (Types 16, 18) Market Facts & Figures by Country
3.7.1 Latin America Human Papillomavirus Vaccine (Types 16, 18) Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Human Papillomavirus Vaccine (Types 16, 18) Sales by Country (2019-2030)
3.7.3 Latin America Human Papillomavirus Vaccine (Types 16, 18) Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Human Papillomavirus Vaccine (Types 16, 18) Market Facts & Figures by Country
3.8.1 Middle East and Africa Human Papillomavirus Vaccine (Types 16, 18) Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Human Papillomavirus Vaccine (Types 16, 18) Sales by Country (2019-2030)
3.8.3 Middle East and Africa Human Papillomavirus Vaccine (Types 16, 18) Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Human Papillomavirus Vaccine (Types 16, 18) Sales by Type (2019-2030)
4.1.1 Global Human Papillomavirus Vaccine (Types 16, 18) Sales by Type (2019-2024)
4.1.2 Global Human Papillomavirus Vaccine (Types 16, 18) Sales by Type (2025-2030)
4.1.3 Global Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Type (2019-2030)
4.2 Global Human Papillomavirus Vaccine (Types 16, 18) Revenue by Type (2019-2030)
4.2.1 Global Human Papillomavirus Vaccine (Types 16, 18) Revenue by Type (2019-2024)
4.2.2 Global Human Papillomavirus Vaccine (Types 16, 18) Revenue by Type (2025-2030)
4.2.3 Global Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Type (2019-2030)
4.3 Global Human Papillomavirus Vaccine (Types 16, 18) Price by Type (2019-2030)
5 Segment by Application
5.1 Global Human Papillomavirus Vaccine (Types 16, 18) Sales by Application (2019-2030)
5.1.1 Global Human Papillomavirus Vaccine (Types 16, 18) Sales by Application (2019-2024)
5.1.2 Global Human Papillomavirus Vaccine (Types 16, 18) Sales by Application (2025-2030)
5.1.3 Global Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Application (2019-2030)
5.2 Global Human Papillomavirus Vaccine (Types 16, 18) Revenue by Application (2019-2030)
5.2.1 Global Human Papillomavirus Vaccine (Types 16, 18) Revenue by Application (2019-2024)
5.2.2 Global Human Papillomavirus Vaccine (Types 16, 18) Revenue by Application (2025-2030)
5.2.3 Global Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Application (2019-2030)
5.3 Global Human Papillomavirus Vaccine (Types 16, 18) Price by Application (2019-2030)
6 Key Companies Profiled
6.1 GlaxoSmithKline
6.1.1 GlaxoSmithKline Corporation Information
6.1.2 GlaxoSmithKline Description and Business Overview
6.1.3 GlaxoSmithKline Human Papillomavirus Vaccine (Types 16, 18) Sales, Revenue and Gross Margin (2019-2024)
6.1.4 GlaxoSmithKline Human Papillomavirus Vaccine (Types 16, 18) Product Portfolio
6.1.5 GlaxoSmithKline Recent Developments/Updates
6.2 Merck & Co., Inc.
6.2.1 Merck & Co., Inc. Corporation Information
6.2.2 Merck & Co., Inc. Description and Business Overview
6.2.3 Merck & Co., Inc. Human Papillomavirus Vaccine (Types 16, 18) Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Merck & Co., Inc. Human Papillomavirus Vaccine (Types 16, 18) Product Portfolio
6.2.5 Merck & Co., Inc. Recent Developments/Updates
6.3 Serum Institute of India
6.3.1 Serum Institute of India Corporation Information
6.3.2 Serum Institute of India Description and Business Overview
6.3.3 Serum Institute of India Human Papillomavirus Vaccine (Types 16, 18) Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Serum Institute of India Human Papillomavirus Vaccine (Types 16, 18) Product Portfolio
6.3.5 Serum Institute of India Recent Developments/Updates
6.4 INNOVAX
6.4.1 INNOVAX Corporation Information
6.4.2 INNOVAX Description and Business Overview
6.4.3 INNOVAX Human Papillomavirus Vaccine (Types 16, 18) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 INNOVAX Human Papillomavirus Vaccine (Types 16, 18) Product Portfolio
6.4.5 INNOVAX Recent Developments/Updates
6.5 ZSSW
6.5.1 ZSSW Corporation Information
6.5.2 ZSSW Description and Business Overview
6.5.3 ZSSW Human Papillomavirus Vaccine (Types 16, 18) Sales, Revenue and Gross Margin (2019-2024)
6.5.4 ZSSW Human Papillomavirus Vaccine (Types 16, 18) Product Portfolio
6.5.5 ZSSW Recent Developments/Updates
6.6 HUMANWELL HEALTHCARE
6.6.1 HUMANWELL HEALTHCARE Corporation Information
6.6.2 HUMANWELL HEALTHCARE Description and Business Overview
6.6.3 HUMANWELL HEALTHCARE Human Papillomavirus Vaccine (Types 16, 18) Sales, Revenue and Gross Margin (2019-2024)
6.6.4 HUMANWELL HEALTHCARE Human Papillomavirus Vaccine (Types 16, 18) Product Portfolio
6.6.5 HUMANWELL HEALTHCARE Recent Developments/Updates
6.7 WALVAX
6.6.1 WALVAX Corporation Information
6.6.2 WALVAX Description and Business Overview
6.6.3 WALVAX Human Papillomavirus Vaccine (Types 16, 18) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 WALVAX Human Papillomavirus Vaccine (Types 16, 18) Product Portfolio
6.7.5 WALVAX Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Human Papillomavirus Vaccine (Types 16, 18) Industry Chain Analysis
7.2 Human Papillomavirus Vaccine (Types 16, 18) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Human Papillomavirus Vaccine (Types 16, 18) Production Mode & Process
7.4 Human Papillomavirus Vaccine (Types 16, 18) Sales and Marketing
7.4.1 Human Papillomavirus Vaccine (Types 16, 18) Sales Channels
7.4.2 Human Papillomavirus Vaccine (Types 16, 18) Distributors
7.5 Human Papillomavirus Vaccine (Types 16, 18) Customers
8 Human Papillomavirus Vaccine (Types 16, 18) Market Dynamics
8.1 Human Papillomavirus Vaccine (Types 16, 18) Industry Trends
8.2 Human Papillomavirus Vaccine (Types 16, 18) Market Drivers
8.3 Human Papillomavirus Vaccine (Types 16, 18) Market Challenges
8.4 Human Papillomavirus Vaccine (Types 16, 18) Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Human Papillomavirus Vaccine (Types 16, 18) Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Human Papillomavirus Vaccine (Types 16, 18) Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Human Papillomavirus Vaccine (Types 16, 18) Market Competitive Situation by Manufacturers in 2023
Table 4. Global Human Papillomavirus Vaccine (Types 16, 18) Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Human Papillomavirus Vaccine (Types 16, 18) Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Human Papillomavirus Vaccine (Types 16, 18), Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Human Papillomavirus Vaccine (Types 16, 18), Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Human Papillomavirus Vaccine (Types 16, 18), Product Type & Application
Table 12. Global Key Manufacturers of Human Papillomavirus Vaccine (Types 16, 18), Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Human Papillomavirus Vaccine (Types 16, 18) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Papillomavirus Vaccine (Types 16, 18) as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Human Papillomavirus Vaccine (Types 16, 18) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Human Papillomavirus Vaccine (Types 16, 18) Sales by Region (2019-2024) & (K Units)
Table 18. Global Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Region (2019-2024)
Table 19. Global Human Papillomavirus Vaccine (Types 16, 18) Sales by Region (2025-2030) & (K Units)
Table 20. Global Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Region (2025-2030)
Table 21. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Region (2019-2024)
Table 23. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Region (2025-2030)
Table 25. North America Human Papillomavirus Vaccine (Types 16, 18) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Human Papillomavirus Vaccine (Types 16, 18) Sales by Country (2019-2024) & (K Units)
Table 27. North America Human Papillomavirus Vaccine (Types 16, 18) Sales by Country (2025-2030) & (K Units)
Table 28. North America Human Papillomavirus Vaccine (Types 16, 18) Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Human Papillomavirus Vaccine (Types 16, 18) Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Human Papillomavirus Vaccine (Types 16, 18) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Human Papillomavirus Vaccine (Types 16, 18) Sales by Country (2019-2024) & (K Units)
Table 32. Europe Human Papillomavirus Vaccine (Types 16, 18) Sales by Country (2025-2030) & (K Units)
Table 33. Europe Human Papillomavirus Vaccine (Types 16, 18) Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Human Papillomavirus Vaccine (Types 16, 18) Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Human Papillomavirus Vaccine (Types 16, 18) Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Human Papillomavirus Vaccine (Types 16, 18) Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Human Papillomavirus Vaccine (Types 16, 18) Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Human Papillomavirus Vaccine (Types 16, 18) Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Human Papillomavirus Vaccine (Types 16, 18) Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Human Papillomavirus Vaccine (Types 16, 18) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Human Papillomavirus Vaccine (Types 16, 18) Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Human Papillomavirus Vaccine (Types 16, 18) Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Human Papillomavirus Vaccine (Types 16, 18) Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Human Papillomavirus Vaccine (Types 16, 18) Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Human Papillomavirus Vaccine (Types 16, 18) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Human Papillomavirus Vaccine (Types 16, 18) Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Human Papillomavirus Vaccine (Types 16, 18) Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Human Papillomavirus Vaccine (Types 16, 18) Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Human Papillomavirus Vaccine (Types 16, 18) Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Human Papillomavirus Vaccine (Types 16, 18) Sales (K Units) by Type (2019-2024)
Table 51. Global Human Papillomavirus Vaccine (Types 16, 18) Sales (K Units) by Type (2025-2030)
Table 52. Global Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Type (2019-2024)
Table 53. Global Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Type (2025-2030)
Table 54. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Type (2019-2024)
Table 57. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Type (2025-2030)
Table 58. Global Human Papillomavirus Vaccine (Types 16, 18) Price (US$/Unit) by Type (2019-2024)
Table 59. Global Human Papillomavirus Vaccine (Types 16, 18) Price (US$/Unit) by Type (2025-2030)
Table 60. Global Human Papillomavirus Vaccine (Types 16, 18) Sales (K Units) by Application (2019-2024)
Table 61. Global Human Papillomavirus Vaccine (Types 16, 18) Sales (K Units) by Application (2025-2030)
Table 62. Global Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Application (2019-2024)
Table 63. Global Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Application (2025-2030)
Table 64. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Application (2019-2024)
Table 67. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Application (2025-2030)
Table 68. Global Human Papillomavirus Vaccine (Types 16, 18) Price (US$/Unit) by Application (2019-2024)
Table 69. Global Human Papillomavirus Vaccine (Types 16, 18) Price (US$/Unit) by Application (2025-2030)
Table 70. GlaxoSmithKline Corporation Information
Table 71. GlaxoSmithKline Description and Business Overview
Table 72. GlaxoSmithKline Human Papillomavirus Vaccine (Types 16, 18) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. GlaxoSmithKline Human Papillomavirus Vaccine (Types 16, 18) Product
Table 74. GlaxoSmithKline Recent Developments/Updates
Table 75. Merck & Co., Inc. Corporation Information
Table 76. Merck & Co., Inc. Description and Business Overview
Table 77. Merck & Co., Inc. Human Papillomavirus Vaccine (Types 16, 18) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Merck & Co., Inc. Human Papillomavirus Vaccine (Types 16, 18) Product
Table 79. Merck & Co., Inc. Recent Developments/Updates
Table 80. Serum Institute of India Corporation Information
Table 81. Serum Institute of India Description and Business Overview
Table 82. Serum Institute of India Human Papillomavirus Vaccine (Types 16, 18) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Serum Institute of India Human Papillomavirus Vaccine (Types 16, 18) Product
Table 84. Serum Institute of India Recent Developments/Updates
Table 85. INNOVAX Corporation Information
Table 86. INNOVAX Description and Business Overview
Table 87. INNOVAX Human Papillomavirus Vaccine (Types 16, 18) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. INNOVAX Human Papillomavirus Vaccine (Types 16, 18) Product
Table 89. INNOVAX Recent Developments/Updates
Table 90. ZSSW Corporation Information
Table 91. ZSSW Description and Business Overview
Table 92. ZSSW Human Papillomavirus Vaccine (Types 16, 18) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. ZSSW Human Papillomavirus Vaccine (Types 16, 18) Product
Table 94. ZSSW Recent Developments/Updates
Table 95. HUMANWELL HEALTHCARE Corporation Information
Table 96. HUMANWELL HEALTHCARE Description and Business Overview
Table 97. HUMANWELL HEALTHCARE Human Papillomavirus Vaccine (Types 16, 18) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. HUMANWELL HEALTHCARE Human Papillomavirus Vaccine (Types 16, 18) Product
Table 99. HUMANWELL HEALTHCARE Recent Developments/Updates
Table 100. WALVAX Corporation Information
Table 101. WALVAX Description and Business Overview
Table 102. WALVAX Human Papillomavirus Vaccine (Types 16, 18) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. WALVAX Human Papillomavirus Vaccine (Types 16, 18) Product
Table 104. WALVAX Recent Developments/Updates
Table 105. Key Raw Materials Lists
Table 106. Raw Materials Key Suppliers Lists
Table 107. Human Papillomavirus Vaccine (Types 16, 18) Distributors List
Table 108. Human Papillomavirus Vaccine (Types 16, 18) Customers List
Table 109. Human Papillomavirus Vaccine (Types 16, 18) Market Trends
Table 110. Human Papillomavirus Vaccine (Types 16, 18) Market Drivers
Table 111. Human Papillomavirus Vaccine (Types 16, 18) Market Challenges
Table 112. Human Papillomavirus Vaccine (Types 16, 18) Market Restraints
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Human Papillomavirus Vaccine (Types 16, 18)
Figure 2. Global Human Papillomavirus Vaccine (Types 16, 18) Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Human Papillomavirus Vaccine (Types 16, 18) Market Share by Type in 2023 & 2030
Figure 4. HPV16 Product Picture
Figure 5. HPV18 Product Picture
Figure 6. Global Human Papillomavirus Vaccine (Types 16, 18) Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Human Papillomavirus Vaccine (Types 16, 18) Market Share by Application in 2023 & 2030
Figure 8. 9-26 Years Old
Figure 9. 26-45 Years Old
Figure 10. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 11. Global Human Papillomavirus Vaccine (Types 16, 18) Market Size (2019-2030) & (US$ Million)
Figure 12. Global Human Papillomavirus Vaccine (Types 16, 18) Sales (2019-2030) & (K Units)
Figure 13. Global Human Papillomavirus Vaccine (Types 16, 18) Average Price (US$/Unit) & (2019-2030)
Figure 14. Human Papillomavirus Vaccine (Types 16, 18) Report Years Considered
Figure 15. Human Papillomavirus Vaccine (Types 16, 18) Sales Share by Manufacturers in 2023
Figure 16. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue Share by Manufacturers in 2023
Figure 17. The Global 5 and 10 Largest Human Papillomavirus Vaccine (Types 16, 18) Players: Market Share by Revenue in 2023
Figure 18. Human Papillomavirus Vaccine (Types 16, 18) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 19. Global Human Papillomavirus Vaccine (Types 16, 18) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 20. North America Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Country (2019-2030)
Figure 21. North America Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Country (2019-2030)
Figure 22. United States Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 23. Canada Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Europe Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Country (2019-2030)
Figure 25. Europe Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Country (2019-2030)
Figure 26. Germany Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. France Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. U.K. Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Italy Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Russia Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Asia Pacific Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Region (2019-2030)
Figure 32. Asia Pacific Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Region (2019-2030)
Figure 33. China Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Japan Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. South Korea Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. India Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Australia Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. China Taiwan Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Indonesia Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Thailand Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Malaysia Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Latin America Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Country (2019-2030)
Figure 43. Latin America Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Country (2019-2030)
Figure 44. Mexico Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Brazil Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Argentina Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Country (2019-2030)
Figure 48. Middle East & Africa Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Country (2019-2030)
Figure 49. Turkey Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Saudi Arabia Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. UAE Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Global Sales Market Share of Human Papillomavirus Vaccine (Types 16, 18) by Type (2019-2030)
Figure 53. Global Revenue Market Share of Human Papillomavirus Vaccine (Types 16, 18) by Type (2019-2030)
Figure 54. Global Human Papillomavirus Vaccine (Types 16, 18) Price (US$/Unit) by Type (2019-2030)
Figure 55. Global Sales Market Share of Human Papillomavirus Vaccine (Types 16, 18) by Application (2019-2030)
Figure 56. Global Revenue Market Share of Human Papillomavirus Vaccine (Types 16, 18) by Application (2019-2030)
Figure 57. Global Human Papillomavirus Vaccine (Types 16, 18) Price (US$/Unit) by Application (2019-2030)
Figure 58. Human Papillomavirus Vaccine (Types 16, 18) Value Chain
Figure 59. Human Papillomavirus Vaccine (Types 16, 18) Production Process
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Distributors Profiles
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
